Boehringer backs $33M can­cer vac­cine play at Switzer­land's AMAL Ther­a­peu­tics

A can­cer vac­cine de­vel­op­er spun out of the Uni­ver­si­ty of Gene­va has gar­nered €29 mil­lion ($32.7 mil­lion) to fu­el its dri­ve in­to the clin­ic. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.